Increasing dissolution of Trospium chloride (cas 10405-02-4) by co-crystallization with urea

Add time:07/31/2019    Source:sciencedirect.com

The search for various solid forms of an active pharmaceutical ingredient (API) is an important step in drug development. Our aim was to prepare co-crystals of Trospium chloride (cas 10405-02-4), an anticholinergic drug used for the treatment of incontinence, and to investigate if they have advantageous properties for drug formulation. Phase identification was done by powder X-ray diffraction and single-crystal X-ray diffraction. The chemical composition was verified by solution NMR and the dissolution rate of the prepared phases was studied by IDR (intrinsic dissolution rate). For further analysis of phase stability and transitions, combined thermal analysis and temperature-resolved X-ray powder diffraction were used. Urea was selected as a co-crystallization partner. Trospium chloride urea (1:1) co-crystal was prepared by a solvent evaporation. From single-crystal data, the co-crystal structure was solved in a space group P21/c and compared to previously published structures of trospium chloride. Intrinsic dissolution rate revealed that the co-crystal dissolves 32% faster than pure API. However, its low thermal and pressure stability makes it a challenging choice for the final drug formulation.

We also recommend Trading Suppliers and Manufacturers of Trospium chloride (cas 10405-02-4). Pls Click Website Link as below: cas 10405-02-4 suppliers

Prev:Trospium chloride (cas 10405-02-4) is absorbed from two intestinal “absorption windows” with different permeability in healthy subjects
Next:Trospium chloride (cas 10405-02-4) for overactive bladder may induce central nervous system adverse events)